Medication-assisted treatment, commonly called MAT, is the use of FDA-approved medications combined with counseling and behavioral therapies to treat substance use disorders. It’s designed as a “whole-patient” approach, meaning medication alone isn’t the full picture. The three components, medication, therapy, and support services, work together to address both the physical and psychological sides of addiction.
How MAT Works for Opioid Use Disorder
The FDA has approved three medications for opioid use disorder, and each one works differently in the brain. Buprenorphine partially activates the same receptors that opioids target, reducing cravings and withdrawal symptoms without producing a full high. Methadone activates those receptors more fully but in a slow, controlled way that prevents the intense rush associated with misuse. Naltrexone takes the opposite approach entirely: it blocks opioid receptors so that even if someone uses opioids, they don’t feel the euphoric effects.
The choice between these medications depends on where someone is in their recovery. Buprenorphine and methadone can be started while a person is still physically dependent on opioids, helping them stabilize without going through severe withdrawal. Naltrexone requires a period of abstinence first, typically 7 to 14 days, because blocking the receptors while opioids are still in the system can trigger sudden withdrawal.
MAT is a key tool in overdose prevention. With prolonged treatment, overdose and relapse rates drop significantly, and over time many people are able to stop illicit drug use permanently. Treatment retention, a strong predictor of long-term success, averages around 75 to 78 percent at three months and roughly 50 to 57 percent at twelve months for both buprenorphine and methadone programs.
How MAT Works for Alcohol Use Disorder
Three FDA-approved medications also exist for alcohol use disorder, and they target different aspects of drinking behavior. Naltrexone (the same drug used for opioid disorder, at a different dose) blocks the brain’s opioid receptors, which are involved in the pleasurable effects of alcohol. By dampening that reward signal, it reduces both euphoria and cravings. It tends to work best for people who have already stopped drinking before starting the medication.
Acamprosate works on a different brain system involved in the anxiety and restlessness that often follow alcohol withdrawal. It helps maintain abstinence in people who have already quit drinking, essentially calming the neurological disruption that makes early sobriety so uncomfortable. Disulfiram takes a purely deterrent approach: it interferes with how your body breaks down alcohol, so drinking while on the medication causes nausea, flushing, and other deeply unpleasant symptoms. It doesn’t reduce cravings at all, but the threat of a bad reaction can be a powerful motivator.
The Role of Counseling and Therapy
Federal regulations require that counseling be part of MAT, particularly for methadone and buprenorphine treatment. This isn’t a formality. Medication addresses the physical mechanics of addiction, but therapy helps people identify the patterns, triggers, and emotional landscapes that drive substance use in the first place.
The most commonly used approach is cognitive behavioral therapy (CBT), endorsed by about 69 percent of treatment program directors as a top counseling method. CBT helps people recognize dysfunctional thinking, change unhelpful behaviors, and build healthier ways of interacting with others. Motivational enhancement therapy ranks a close second, used by about 63 percent of programs. It draws on motivational interviewing techniques to help people clarify their own goals and strengthen their internal drive to change, rather than relying on external pressure.
Other options include contingency management (which uses tangible rewards for meeting treatment goals), community reinforcement approaches, family therapy, peer support services, and even phone or computer-based interventions. The intensity of counseling often shifts over time. During the early stabilization phase, sessions tend to be more frequent. As someone settles into maintenance, therapy can become less intensive.
How Long Treatment Lasts
There is no single recommended duration for MAT. Clinical guidelines consistently emphasize that longer treatment produces better outcomes, and that detoxification alone, without ongoing maintenance, leads to poor results over time. The World Health Organization notes that treatment lasting years may be necessary for opioid use disorder.
For opioid use disorder, tapering off buprenorphine is generally a slow process accomplished over several months, and clinical guidelines recommend it only when specific conditions are met: the patient wants to discontinue, they have stable housing and income, and they have adequate support in their personal life. Rushing this process increases the risk of relapse.
For alcohol use disorder, the risk of relapse is highest in the first 6 to 12 months after quitting and gradually decreases over several years. A minimum of six months of medication is typically recommended, with treatment continuing for one to two years if the person is responding well. If someone continues drinking 4 to 6 weeks after starting acamprosate or naltrexone, guidelines recommend stopping that particular medication and reassessing the treatment plan.
Who Can Prescribe MAT
Access to MAT medications has expanded significantly in recent years. Before 2023, doctors needed a special federal waiver (called the X-waiver) to prescribe buprenorphine, and they were limited in how many patients they could treat. The Consolidated Appropriations Act of 2023 eliminated both of those barriers. Any practitioner with a standard DEA registration that includes Schedule III authority can now prescribe buprenorphine for opioid use disorder, with no cap on patient numbers.
New or renewing DEA registrants do need to complete at least eight hours of training on substance use disorders, unless they hold board certification in addiction medicine or addiction psychiatry, or graduated within the past five years from a program that included equivalent coursework. State laws still apply on top of these federal rules and may impose additional requirements, so regulations can vary depending on where you live.
Methadone for opioid use disorder is handled differently. It can only be dispensed through federally certified opioid treatment programs, which means patients typically visit a clinic to receive their dose rather than filling a prescription at a regular pharmacy. Naltrexone, by contrast, can be prescribed by any healthcare provider and picked up at a standard pharmacy.
Why It’s Called “Whole-Patient” Treatment
The philosophy behind MAT is that addiction is not a single problem with a single fix. Medication stabilizes brain chemistry so a person can function without the constant pull of cravings or the fear of withdrawal. Therapy builds the skills and self-awareness needed to sustain recovery over years. And the broader support structure, whether that’s stable housing, employment assistance, or peer networks, addresses the life circumstances that often fuel substance use in the first place.
People sometimes question whether MAT simply replaces one substance with another. The clinical reality is that these medications, taken as prescribed, don’t produce the destructive cycle of intoxication and withdrawal that defines addiction. They restore enough neurological stability for someone to hold a job, maintain relationships, and engage meaningfully in their own recovery. For many people, that stability is what makes lasting change possible.